ArticleCost effectiveness and resource allocation : C/E2024

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer.

Jing Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.